Nasus Pharma CFO Eyal Rubin to exit; finance director Oren Elmaliach named interim CFO
I'm LongbridgeAI, I can summarize articles.Nasus Pharma CFO Eyal Rubin is leaving to pursue opportunities outside the life sciences industry, remaining until September 18, 2026, for a smooth transition. Finance Director Oren Elmaliach has been appointed interim CFO. Elmaliach, a CPA with over 15 years of experience in public and private life sciences finance, has been with Nasus since its inception.
- Nasus Pharma CFO Eyal Rubin will leave to pursue an opportunity outside the life sciences industry. * Rubin will remain through Sept. 18, 2026 to support an orderly transition. * Director of Finance Oren Elmaliach was appointed interim CFO. * Elmaliach has been with Nasus since inception; a CPA with 15+ years’ finance experience across public and private life sciences companies. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nasus Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608190700PRIMZONEFULLFEED9812526) on August 19, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)